On May, 16 Codexis, Inc. (CDXS) Sets 1-Year High at $14.11

May 16, 2018 - By Joseph Norton

Codexis, Inc. (NASDAQ:CDXS) Corporate Logo

During 2017 Q4 the big money sentiment decreased to 2.17. That’s change of 0.03, from 2017Q3’s 2.2. 3 investors sold all, 15 reduced holdings as Codexis, Inc. ratio dropped. 27 grew positions while 12 funds amassed positions. Funds hold 28.02 million shares thus 9.42% more from 2017Q3’s 25.60 million shares.
Legal General Gru Public Ltd Company accumulated 9,457 shs. Deutsche State Bank Ag stated it has 107,089 shs. Credit Suisse Ag invested in 0% or 11,766 shs. Metropolitan Life Insur holds 0% or 10,879 shs in its capital. Blackrock Inc accumulated 0% or 2.67 million shs. 34,400 are held by State Common Retirement Fund. Goldman Sachs Group owns 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 41,931 shs. 429,439 are held by Northern Trust. Strs Ohio holds 0% or 88,800 shs in its capital. Tower Research Ltd Liability (Trc) owns 10,400 shs for 0.01% of their capital. Laurion Capital Mgmt Limited Partnership has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Tiaa Cref Mngmt Ltd Liability holds 97,385 shs. Royal Bankshares Of Canada invested in 0% or 42,147 shs. State Street holds 0% or 645,477 shs. Voya Investment Mngmt Lc stated it has 0% of its capital in Codexis, Inc. (NASDAQ:CDXS).

Codexis, Inc. registered $1.19 million net activity with 0 insider purchases and 5 insider sales since March 21, 2018. Another trade for 25,000 shs valued at $276,318 was sold by BARUCH THOMAS R. On Monday, March 26 WOLF DENNIS P sold $464,384 worth of Codexis, Inc. (NASDAQ:CDXS) or 41,666 shs. Shares for $62,213 were sold by Smith David V. KELLEY BERNARD J had sold 10,206 shs worth $124,683.

Codexis, Inc. (NASDAQ:CDXS) touched yearly high touching $14.11. Our price target is $15.24. Barchart.com reported it on May, 16. It has $751.49 million MC. At $15.24 stock price target, the company valuation changes by $60.12M more.

CDXS is hitting $14.11 during the last trading session, after increased 6.53%.Codexis, Inc. has 492,171 shares volume, 17.42% up from normal. CDXS is uptrending and has moved 125.77% since May 16, 2017. CDXS outperformed by 114.22% the S&P500.

On August, 8 Codexis, Inc. (NASDAQ:CDXS)’s earnings release is awaited by WallStreet, as reported by Faxor. earnings per share of $-0.03 is 76.92 % up from 2017’s $-0.13 EPS. Analysts at Wall Street see Codexis, Inc.’s -70.00 % EPS growth compared to $-0.10 earnings per share for previous quarter.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

In total 2 analysts cover Codexis (NASDAQ:CDXS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CDXS) has 100% bullish analysts. With $1600 highest and $11.5 lowest PT, Codexis has $13.75 average PT or -2.55% below the current ($14.11) price. 2 are the (NASDAQ:CDXS)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Monday, March 12 the company was maintained by H.C. Wainwright. On Wednesday, May 16 Stephens initiated Codexis, Inc. (NASDAQ:CDXS) rating. Stephens has “Buy” rating and $1600 target.

A couple more Codexis, Inc. (NASDAQ:CDXS) news were brought out by: Globenewswire.com which released on May 03, 2018 “Codexis to Hold First Quarter 2018 Conference Call on May 10”, also Globenewswire.com on May 10, 2018 brought out “Codexis Reports First Quarter 2018 Financial Results”, the next Seekingalpha.com is “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018. Nasdaq.com has article titled “3 High-Growth Stocks That Are Just Getting Started”.

Codexis, Inc. discovers, develops, and sells protein catalysts.The company has $751.49 million market cap. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening.Last it reported negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: